// App-Quantinova.ai

583 : Ultrasensitive Next-Generation Sequencing-Based Measurable Residual Disease Assessment in Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia after Frontline Therapy: Correlation with Flow Cytometry and Impact on Clinical Outcomes

Researchers

Presenter

  • Nicholas J. Short

Principal Investigators

  • Hagop M. Kantarjian

  • Keyur Patel

  • Steven M. Kornblau

  • Jeffrey L. Jorgensen

  • Sa A Wang

  • Marina Konopleva

  • Nitin Jain

  • Partow Kebriaei

  • Musa Yilmaz

  • Ghayas C. Issa

  • Jairo A. Matthews

  • Munazza Noor

  • Rebecca Garris

  • Farhad Ravandi

  • Elias Jabbour

Medical Centers

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Section of Nephrology, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Department of Leukemia, Universit Y of Texas At Houston, Houston, TX

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

Biomarkers

  • Breakpoint Cluster Region

Drug/Treatment

  • Inotuzumab ozogamicin

Outcome

  • N/A

Study Design

  • Adaptive

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved